News

Technology News

VistaGen And WARF Sign Stem Cell Agreement

Friday, December 19, 2008 5:02:00 AM PDT | VentureDeal Staff
South San Francisco, California  --  Biotechnology company VistaGen Therapeutics and the Wisconsin Alumni Research Foundation announced that they have signed a license for a number of human embryonic stem cell patents.

The licensed patents will help accelerate VistaGen's commercial programs for providing stem cell-based predictive toxicology and screening assays for preclinical research and development.

“This agreement with WARF is another critical step in our strategy to become a ‘one-stop-shop’ for the world’s premier stem cell differentiation systems,” said Dr. Ralph Snodgrass, VistaGen’s CEO.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1